238.22MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Canopy Growth Corp
Currency: USD Updated: 2025-11-06 Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Canopy Growth Corp's Score
Score Analysis
Current score
Previous score
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Canopy Growth Corp Highlights
StrengthsRisks
Financial Health
Currency: USD Updated: 2025-11-06The company's current financial score is 7.12, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 52.43M, representing a year-over-year increase of 8.72%, while its net profit experienced a year-over-year increase of 132.60%.
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Key Metrics
Total revenue
Operating profit
Total assets
SG&A
No Data
Key Metrics
Cash flow from operating activities
Income after tax
No Data
Key Metrics
Cash flow from operating activities
Total revenue
No Data
Key Metrics
No Data
Canopy Growth Corp's Company Valuation
Currency: USD Updated: 2025-11-06The company’s current valuation score is 8.74, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -0.28, which is -76.03% below the recent high of -0.07 and -917.84% above the recent low of -2.87.
Valuation Dimensions
Industry Ranking 109/159
No Data
Earnings Forecast
Currency: USD Updated: 2025-11-06The company’s current earnings forecast score is 6.00, which is lower than the Pharmaceuticals industry's average of 7.77. The average price target for Canopy Growth Corp is 3.65, with a high of 3.65 and a low of 3.65.
Support & Resistance
No Data
Strong Buy
Buy
Hold
Sell
Strong Sell
Vertex Pharmaceuticals Inc
VRTX
33
Financial Forecasting
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-11-06The company’s current price momentum score is 4.93, which is lower than the Pharmaceuticals industry's average of 6.90. Sideways: Currently, the stock price is trading between the resistance level at 1.43 and the support level at 0.92, making it suitable for range-bound swing trading.
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Institutional Confidence
Currency: USD Updated: 2025-11-06Institutional Shareholding
No Data
Shareholder Activity
Global X Investments Canada Inc.
Susquehanna International Group, LLP
Millennium Management LLC
Goldman Sachs & Company, Inc.
Morgan Stanley Canada Limited
Risk Assessment
Currency: USD Updated: 2025-11-06The company’s current risk assessment score is 2.68, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 2.15. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Beta vs S&P 500 index
2.15
240-Day Maximum Drawdown
+80.04%
240-Day Volatility
+103.22%
Volatility
Downside Risk-Adjusted Return
Maximum Daily Upside Volatility
Maximum Daily Downside Volatility
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ligand Pharmaceuticals Inc
LGND
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
